Treats acne vulgaris. Sold as Ziana, Veltin. Every FDA application for this active ingredient: 2 branded and 3 generic.
As of Nov 16, 2026, FDA lists 5 applications for Clindamycin Phosphate; Tretinoin (sold as Ziana, Veltin), first approved Nov 7, 2006, with 0 new uses approved and 0 published complete response letters.
| Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate AcneAcne Vulgaris · Nishtar Medical University | Phase 4 | Recruiting | Nov 4, 2026 |
| The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne TreatmentAcne Vulgaris · Universitas Padjadjaran | Phase 2 | Not yet recruiting | Apr 13, 2025 |
| Nov 7, 2006 | ZianaNDA 50802 · New combination | Bausch | 6 | Marketed |
| Jul 16, 2010 | VeltinNDA 50803 · New formulation or manufacturer | Chartwell Rx | 0 | Marketed |
| Jun 12, 2015 | Clindamycin Phosphate And TretinoinANDA 202564 | Actavis Mid Atlantic | 0 | Marketed |
| Feb 10, 2022 | Clindamycin Phosphate And TretinoinANDA 212845 | Solaris Pharma Corp | 0 | Marketed |
| Sep 1, 2023 | Clindamycin Phosphate And TretinoinANDA 216943 | Encube | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA